[go: up one dir, main page]

MA34002B1 - Thérapie antivirale - Google Patents

Thérapie antivirale

Info

Publication number
MA34002B1
MA34002B1 MA35145A MA35145A MA34002B1 MA 34002 B1 MA34002 B1 MA 34002B1 MA 35145 A MA35145 A MA 35145A MA 35145 A MA35145 A MA 35145A MA 34002 B1 MA34002 B1 MA 34002B1
Authority
MA
Morocco
Prior art keywords
antiviral therapy
treatment
hiv
aids
combinations
Prior art date
Application number
MA35145A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA34002B1 publication Critical patent/MA34002B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des combinaisons de composés comprenant des inhibiteurs de l'intégrase du vih et d'autres agents thérapeutiques. Lesdites combinaisons peuvent être utilisées dans le cadre de l'inhibition de la réplication du vih, de la prévention et/ou du traitement de l'infection par le vih et du traitement du sida et/ou du syndrome pré-sida.
MA35145A 2010-01-27 2011-01-24 Thérapie antivirale MA34002B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Publications (1)

Publication Number Publication Date
MA34002B1 true MA34002B1 (fr) 2013-02-01

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35145A MA34002B1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Country Status (45)

Country Link
US (13) US20120295898A1 (fr)
EP (6) EP3127542B1 (fr)
JP (9) JP2013518107A (fr)
KR (4) KR20170078868A (fr)
CN (2) CN102791129B (fr)
AP (1) AP3551A (fr)
AU (1) AU2011209788C1 (fr)
BR (1) BR112012018670A2 (fr)
CA (4) CA2967453C (fr)
CL (1) CL2012002080A1 (fr)
CO (1) CO6602152A2 (fr)
CR (1) CR20120423A (fr)
CY (6) CY1116509T1 (fr)
DK (4) DK3127542T3 (fr)
DO (2) DOP2012000205A (fr)
EA (4) EA032868B1 (fr)
EC (1) ECSP12012106A (fr)
ES (4) ES2543066T3 (fr)
FI (2) FI3494972T3 (fr)
FR (2) FR18C1043I2 (fr)
HK (1) HK1250335A1 (fr)
HR (4) HRP20240168T1 (fr)
HU (6) HUE037812T2 (fr)
IL (5) IL221007A (fr)
LT (5) LT3494972T (fr)
LU (1) LUC00090I2 (fr)
MA (1) MA34002B1 (fr)
ME (2) ME03058B (fr)
MX (4) MX367937B (fr)
MY (3) MY202778A (fr)
NO (2) NO2932970T3 (fr)
NZ (4) NZ627827A (fr)
PE (2) PE20121524A1 (fr)
PH (3) PH12012501537A1 (fr)
PL (4) PL3127542T3 (fr)
PT (4) PT3494972T (fr)
RS (4) RS57323B1 (fr)
SG (3) SG182614A1 (fr)
SI (4) SI2932970T1 (fr)
SM (4) SMT202400063T1 (fr)
TN (1) TN2012000376A1 (fr)
TR (1) TR201807704T4 (fr)
UA (1) UA105556C2 (fr)
WO (1) WO2011094150A1 (fr)
ZA (1) ZA201205586B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
KR20150084772A (ko) 2012-10-23 2015-07-22 시플라 리미티드 약학 항레트로바이러스 조성물
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EP2767272A1 (fr) * 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
WO2014125124A1 (fr) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Forme galénique pharmaceutique solide de dolutegravir
NO2865735T3 (fr) 2013-07-12 2018-07-21
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
IN2014MU00916A (fr) 2014-03-20 2015-09-25 Cipla Ltd
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (fr) 2014-06-20 2018-06-23
EP3177629B1 (fr) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Nouveaux hydrates de sodium de dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (fr) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Composes carbamoylpyridones polycycliques et leur utilisation pharmaceutique
WO2017029225A1 (fr) * 2015-08-14 2017-02-23 Sandoz Ag Composition pharmaceutique solide d'abacavir, de lamivudine et d'efavirenz
WO2017205585A1 (fr) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
WO2018028841A1 (fr) * 2016-08-12 2018-02-15 Sandoz Ag Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
WO2018042332A1 (fr) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
WO2019016679A1 (fr) * 2017-07-18 2019-01-24 Viiv Healthcare Company Polythérapie
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
CA3078624A1 (fr) * 2017-10-13 2019-04-18 Viiv Healthcare Company Formulation de comprime pharmaceutique bicouche
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
US20230270677A1 (en) * 2020-01-09 2023-08-31 University Of Washington Long-acting therapeutic agent combinations and methods thereof
WO2021173522A1 (fr) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (fr) 1998-03-27 2001-01-03 The Regents of the University of California Nouveaux inhibiteurs de vih integrase et traitement du vih fonde sur des combinaisons de medicaments contenant des inhibiteurs d'integrase
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
DE20122916U1 (de) 2000-01-31 2009-12-10 Cook Biotech, Inc., West Lafayette Stentventil
PT1377556E (pt) 2001-04-10 2007-06-06 Pfizer Ltd Derivados de pirazole para tratamento do hiv
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
CA2481890A1 (fr) 2002-06-27 2004-01-08 Medivir Ab Interaction synergique d'abacavir et d'alovudine
JP4996241B2 (ja) * 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2005211733A1 (en) * 2004-02-11 2005-08-25 Shionogi & Co., Ltd HIV integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
DE602005010413D1 (de) * 2004-04-14 2008-11-27 Zhenhong R Cai Phosphonatanaloga von hiv-integrasehemmerverbindungen
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR20070043043A (ko) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
KR101242962B1 (ko) 2004-09-17 2013-03-13 아이데닉스 파마슈티칼스, 인코포레이티드 Ｈｉｖ 억제제로서의 포스포인돌
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
JP2008531716A (ja) 2005-03-04 2008-08-14 スミスクライン ビーチャム コーポレーション 化合物
US8129385B2 (en) * 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
UA101141C2 (ru) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Способ улучшения фармакокинетики ингибиторов интегразы вич
EA018544B1 (ru) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
EP2069303B1 (fr) 2006-07-21 2016-03-30 Gilead Sciences, Inc. Inhibiteurs de protease antiviraux
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
WO2008103899A1 (fr) 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Préparation et utilisation d'inhibiteurs de la transcriptase inverse non nucléosidique
EP2118082B1 (fr) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulateurs de propriétés pharmacocinétiques de produits thérapeutiques
CN101784532B (zh) 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
DK2175857T3 (da) * 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
WO2009058923A1 (fr) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
CN101990534A (zh) 2007-11-01 2011-03-23 Uab研究基金会 治疗和预防病毒感染
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
EP2250185A4 (fr) * 2008-01-03 2011-11-16 Virochem Pharma Inc Nouveaux dérivés de lupane
EP2240504A1 (fr) 2008-01-03 2010-10-20 Virochem Pharma Inc. Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
CA2710679A1 (fr) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibiteurs du cytrochrome p450
CA2714049A1 (fr) 2008-02-14 2009-08-20 Virochem Pharma Inc. Nouveaux derives de 17ss-lupane
WO2009148600A2 (fr) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Composés à base de lysine deutérée
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
EP2376080B1 (fr) * 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthèse d'inhibiteurs carbamoylpyridone de l'intégrase du vih et intermédiaires
EP2376453B1 (fr) 2008-12-11 2019-11-20 VIIV Healthcare Company Intermédiaires pour inhibiteurs de la carbomoylpyridone intégrase du hiv
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (fr) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
JP2021091705A (ja) 2021-06-17
US20120295898A1 (en) 2012-11-22
LTC2932970I2 (lt) 2022-04-25
MY202778A (en) 2024-05-21
PL3127542T3 (pl) 2019-03-29
EA201290583A1 (ru) 2013-04-30
DOP2021000147A (es) 2022-01-16
BR112012018670A2 (pt) 2018-02-06
PH12016500195A1 (en) 2016-12-05
SMT201500177B (it) 2015-09-07
EP2932970A1 (fr) 2015-10-21
MX367938B (es) 2019-09-12
CN105311033B (zh) 2019-05-07
EP2932970B1 (fr) 2018-03-21
CY1120457T1 (el) 2019-07-10
AP2012006445A0 (en) 2012-08-31
JP2018127473A (ja) 2018-08-16
PH12018502489A1 (en) 2020-06-15
PL3494972T3 (pl) 2024-05-27
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
EP2531027B1 (fr) 2015-05-06
ES2543066T3 (es) 2015-08-14
SMT201800594T1 (it) 2019-01-11
HK1209629A1 (en) 2016-04-08
CY2018029I2 (el) 2019-07-10
ME03058B (fr) 2019-01-20
IL245182A0 (en) 2016-06-30
US20200230147A1 (en) 2020-07-23
IL281959B (en) 2021-12-01
EP3351249A1 (fr) 2018-07-25
MY188334A (en) 2021-11-30
RS57728B1 (sr) 2018-12-31
EA202190473A3 (ru) 2021-12-31
CY1121040T1 (el) 2019-12-11
DK2932970T3 (en) 2018-05-28
US20160339033A1 (en) 2016-11-24
UA105556C2 (uk) 2014-05-26
NZ627824A (en) 2016-02-26
CA2787691A1 (fr) 2011-08-04
CA3003988A1 (fr) 2011-08-04
JP2016145204A (ja) 2016-08-12
EP4316599A2 (fr) 2024-02-07
CL2012002080A1 (es) 2012-11-30
LTPA2018013I1 (lt) 2018-11-12
SMT201800290T1 (it) 2018-07-17
EP2531027A1 (fr) 2012-12-12
HUS1800042I1 (hu) 2018-11-28
LTC3494972I2 (fr) 2025-11-10
DK3494972T3 (da) 2024-01-29
JP2019167371A (ja) 2019-10-03
EP2531027A4 (fr) 2013-07-03
JP2023085431A (ja) 2023-06-20
IL267658A (en) 2019-08-29
ME02182B (me) 2015-10-20
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
FI3494972T3 (fi) 2024-03-01
EP3494972A1 (fr) 2019-06-12
EP3494972B1 (fr) 2023-12-13
CY1126771T1 (el) 2025-05-09
US11234985B2 (en) 2022-02-01
DK2531027T3 (en) 2015-07-20
NZ627826A (en) 2016-01-29
MX356891B (es) 2018-06-19
AP3551A (en) 2016-01-18
CY2024017I1 (el) 2025-05-09
ECSP12012106A (es) 2013-05-31
CR20120423A (es) 2012-11-22
EA202190473A2 (ru) 2021-06-30
KR101830715B1 (ko) 2018-04-04
RS65183B1 (sr) 2024-03-29
KR101964923B1 (ko) 2019-04-02
CY2018029I1 (el) 2019-07-10
SI3127542T1 (sl) 2018-11-30
WO2011094150A1 (fr) 2011-08-04
FR18C1043I1 (fr) 2018-11-30
HRP20180855T1 (hr) 2018-06-29
HUE065569T2 (hu) 2024-06-28
JP2013518107A (ja) 2013-05-20
AU2011209788A1 (en) 2012-08-16
CN105311033A (zh) 2016-02-10
RS54123B1 (sr) 2015-12-31
NZ601319A (en) 2014-08-29
KR20180078358A (ko) 2018-07-09
LUC00090I2 (fr) 2019-01-08
TR201807704T4 (tr) 2018-06-21
KR20160111536A (ko) 2016-09-26
PE20121524A1 (es) 2012-12-03
JP6268386B2 (ja) 2018-01-31
FR18C1043I2 (fr) 2019-10-11
HUE026849T2 (en) 2016-08-29
EP3127542A1 (fr) 2017-02-08
HRP20150770T1 (hr) 2015-08-28
TN2012000376A1 (en) 2014-01-30
LT3127542T (lt) 2018-11-26
US20170079982A1 (en) 2017-03-23
ES2688925T3 (es) 2018-11-07
EA201690872A3 (ru) 2016-12-30
ES2670811T3 (es) 2018-06-01
LT3494972T (lt) 2024-03-12
PL2932970T3 (pl) 2018-08-31
RS57323B1 (sr) 2018-08-31
HK1179522A1 (en) 2013-10-04
CO6602152A2 (es) 2013-01-18
PH12012501537A1 (en) 2018-02-07
PT3127542T (pt) 2018-11-26
NZ627827A (en) 2016-02-26
PH12016500195B1 (en) 2021-08-04
US20180200254A1 (en) 2018-07-19
HRP20181531T1 (hr) 2018-11-16
IL257267A (en) 2018-03-29
EA032868B1 (ru) 2019-07-31
EA025176B1 (ru) 2016-11-30
DOP2012000205A (es) 2012-10-15
EA037601B1 (ru) 2021-04-20
EP4316599A3 (fr) 2024-04-10
CA3060290A1 (fr) 2011-08-04
JP2017008087A (ja) 2017-01-12
SMT202400063T1 (it) 2024-03-13
PT2531027E (pt) 2015-09-16
CA3003988C (fr) 2020-01-07
SG10201509476RA (en) 2015-12-30
DK3127542T3 (en) 2018-11-12
CA3060290C (fr) 2022-07-12
KR20120128640A (ko) 2012-11-27
MY207233A (en) 2025-02-07
EP3127542B1 (fr) 2018-08-22
KR20170078868A (ko) 2017-07-07
AU2011209788C1 (en) 2014-08-28
CA2967453C (fr) 2018-07-17
SI2932970T1 (en) 2018-07-31
EA201690872A2 (ru) 2016-08-31
LTPA2024516I1 (fr) 2024-06-25
US20170216284A1 (en) 2017-08-03
JP7724619B2 (ja) 2025-08-18
PT2932970T (pt) 2018-06-08
AU2011209788B2 (en) 2014-02-06
HUE040554T2 (hu) 2019-03-28
SI3494972T1 (sl) 2024-03-29
HK1250335A1 (en) 2018-12-14
EA201892277A1 (ru) 2019-03-29
PL2531027T3 (pl) 2016-01-29
SG182614A1 (en) 2012-08-30
LT2932970T (lt) 2018-06-25
JP2022071126A (ja) 2022-05-13
IL267658B (en) 2021-04-29
US20150238496A1 (en) 2015-08-27
US20180098992A1 (en) 2018-04-12
CA2967453A1 (fr) 2011-08-04
SI2531027T1 (sl) 2015-08-31
JP2025131664A (ja) 2025-09-09
FR24C1024I2 (fr) 2025-06-27
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
NO2932970T3 (fr) 2018-08-18
NO2018036I1 (no) 2018-10-15
CY1116509T1 (el) 2017-03-15
CA2787691C (fr) 2018-07-17
PT3494972T (pt) 2024-02-12
IL221007A0 (en) 2012-09-24
MX2012008774A (es) 2012-08-17
US20170281636A1 (en) 2017-10-05
US20250017939A1 (en) 2025-01-16
SG10201707183TA (en) 2017-10-30
IL245182B (en) 2018-04-30
CN102791129A (zh) 2012-11-21
ES2969969T3 (es) 2024-05-23
IL281959A (en) 2021-05-31
KR101883750B1 (ko) 2018-07-31
CY2024017I2 (el) 2025-05-09
HUE037812T2 (hu) 2018-09-28
HUS2400017I1 (hu) 2024-06-28
CN102791129B (zh) 2015-09-30
US20170119777A1 (en) 2017-05-04
US10426780B2 (en) 2019-10-01
MX367937B (es) 2019-09-12
US20210401850A1 (en) 2021-12-30
FIC20240016I1 (fi) 2024-05-31
US20160199379A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
MA34002B1 (fr) Thérapie antivirale
MA44674A (fr) Inhibiteurs de bromodomaine
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MY186986A (en) Compositions and methods of use of phorbol esters
EP2555798A4 (fr) Procédés et compositions pour l'inhibition de la transmission du vih
WO2015126930A3 (fr) Pharmacothérapie à effet "booster" pour lutter contre les infections à mycobacterium
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
TW200738700A (en) HIV integrase inhibitors
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales